Virtu Financial LLC Galectin Therapeutics Inc Transaction History

Virtu Financial LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$2.13 - $4.2 $23,926 - $47,178	11,233 New	11,233 $25,000
Q4 2022 Feb 15, 2023	BUY	$1.03 - $1.66 $27,135 - $43,732	26,345 Added 205.44%	39,169 $44,000
Q3 2022 Nov 07, 2022	BUY	$1.31 - $2.48 $16,799 - $31,803	12,824 New	12,824 $21,000
Q2 2022 Aug 09, 2022	SELL	$1.19 - $1.74 $19,350 - $28,294	-16,261 Closed	0 $0
Q1 2022 May 17, 2022	SELL	$1.61 - $2.31 $2,257 - $3,238	-1,402 Reduced 7.94%	16,261 $26,000
Q4 2021 Feb 17, 2022	BUY	$2.07 - $3.8 $36,562 - $67,119	17,663 New	17,663 $37,000
Q2 2021 Sep 17, 2021	SELL	$2.07 - $5.1 $30,393 - $74,883	-14,683 Closed	0 $0
Q1 2021 May 19, 2021	BUY	$1.96 - $2.57 $28,778 - $37,735	14,683 New	14,683 $32,000
Q2 2020 Aug 07, 2020	SELL	$1.66 - $3.15 $90,865 - $172,424	-54,738 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$2.79 - $4.32 $152,719 - $236,468	54,738 New	54,738 $157,000
Q4 2018 Jan 16, 2019	SELL	$3.43 - $5.74 $60,889 - $101,896	-17,752 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$3.68 - $6.93 $65,327 - $123,021	17,752 New	17,752 $107,000

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $123M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.